Opportunity Overview
1) Brief description of the context of the research including potential impact
Lung cancer screening invites high risk subjects to have a CT scan of their lungs to identify early treatable lung cancer. By 2028 approximately 500-750,000 subjects will have a CT scan of their lungs annually in the National UK lung cancer screening program. 2-3% of screened subjects will have a lung cancer. Lung cancers can show differing rates of growth and spread to lymph nodes, and some lung cancers, despite treatment can recur. Identifying potentially aggressive lung cancers at an early stage could transform lung cancer management worldwide. Cancers expected to be aggressive could be treatment with extra chemotherapy prior to surgery.
Our study will analyse data from two UCL studies: SUMMIT and ASCENT. The SUMMIT study is one of the largest lung cancer screening studies in the world which has scanned >13,000 subjects annually to identify lung cancer. The ASCENT study comprises all SUMMIT study patients where a lung cancer was diagnosed. The cancers in the ASCENT study have been genotyped and have longitudinal outcome data collected.
This study aims to correlate imaging features of lung cancer growth with clinical and genomic mutational markers of aggression.
2) Aims and Objectives
The specific objectives are to:
- Identify image-based features of malignant lung nodules on low-dose CT scans that predict aggressive disease.
- Evaluate mediastinal lymph node change as a predictor of aggressive disease.
- Identify genomic signatures on imaging data that can predict aggressive disease.
3) Novelty of Research Methodology
- Defining aggression in early lung cancer. Aggression currently has no formal medical definition, but creating this could be valuable for many cancer types.
- Use of time-series deep learning models on medical imaging considering lung and extra-lung features to predict disease progression.
- Novel histopathological-genomic-imaging correlations to delineate a...
Lung cancer screening invites high risk subjects to have a CT scan of their lungs to identify early treatable lung cancer. By 2028 approximately 500-750,000 subjects will have a CT scan of their lungs annually in the National UK lung cancer screening program. 2-3% of screened subjects will have a lung cancer. Lung cancers can show differing rates of growth and spread to lymph nodes, and some lung cancers, despite treatment can recur. Identifying potentially aggressive lung cancers at an early stage could transform lung cancer management worldwide. Cancers expected to be aggressive could be treatment with extra chemotherapy prior to surgery.
Our study will analyse data from two UCL studies: SUMMIT and ASCENT. The SUMMIT study is one of the largest lung cancer screening studies in the world which has scanned >13,000 subjects annually to identify lung cancer. The ASCENT study comprises all SUMMIT study patients where a lung cancer was diagnosed. The cancers in the ASCENT study have been genotyped and have longitudinal outcome data collected.
This study aims to correlate imaging features of lung cancer growth with clinical and genomic mutational markers of aggression.
2) Aims and Objectives
The specific objectives are to:
- Identify image-based features of malignant lung nodules on low-dose CT scans that predict aggressive disease.
- Evaluate mediastinal lymph node change as a predictor of aggressive disease.
- Identify genomic signatures on imaging data that can predict aggressive disease.
3) Novelty of Research Methodology
- Defining aggression in early lung cancer. Aggression currently has no formal medical definition, but creating this could be valuable for many cancer types.
- Use of time-series deep learning models on medical imaging considering lung and extra-lung features to predict disease progression.
- Novel histopathological-genomic-imaging correlations to delineate a...
This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.
Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start FreeSolicitation Details
| Issuing agency | EPSRC |
|---|---|
| Country | United Kingdom |
| Category | Research Development |
| Published | September 30, 2023 |
| Procurement stage | Active solicitation |
| Response due | September 29, 2027 |
| Status | Open — accepting responses |
| Official source | View original notice |
| Last verified | August 12, 2026 |
Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.
Related Opportunities in United Kingdom
See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Get a free United Kingdom Research Development intelligence report in your inbox
A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.